UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044175
Receipt number R000050427
Scientific Title Effect of Daily Intake of Test Food on Intestinal Environment : A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study
Date of disclosure of the study information 2022/08/05
Last modified on 2022/04/05 10:06:27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of Daily Intake of Test Food on Intestinal Environment : A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study

Acronym

Effect of Daily Intake of Test Food on Intestinal Environment

Scientific Title

Effect of Daily Intake of Test Food on Intestinal Environment : A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study

Scientific Title:Acronym

Effect of Daily Intake of Test Food on Intestinal Environment

Region

Japan


Condition

Condition

Healthy Adult

Classification by specialty

Not applicable

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To prove the effect of test food on intestinal environment associated with 4 week daily intake in a randomized, double-blind, placebo-controlled, parallel group study.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Bowel diary at 4 weeks after beginning the intake of test food.

Key secondary outcomes

Intestinal flora, gut metabolome, heart rate variability, sleeping record, electroencephalogram during sleeping, survey on subjects' sleeping and mental and physical conditions, blood metabolome, analysis of fecal samples, the Japanese version of constipation assessment scale MT version (CAS-MT), blood inflammatory marker.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation

NO

Institution consideration


Blocking


Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Daily ingestion 5 tablets of active test food for 4 weeks.

Interventions/Control_2

Daily ingestion 5 tablets of placebo test food for 4 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1. Subjects who agree to participate in this study with a written informed consent.
2. Subjects with ailment on defecation.

Key exclusion criteria

1. Subjects with a clinical history of gastrointestinal cancer or currently under treatment or anti-tumor medication.
2. Subjects with gastrointestinal disorders.
3. Subjects who use gastrointestinal drugs or female hormone once or more a week.
4. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities.
5. Subjects with major surgical history relevant to the digestive system.
6. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data.
7. Subjects with severe anemia.
8. Pre- or post-menopausal women complaining of obvious physical changes.
9. Subjects who repeat constipation and diarrhea.
10. Subjects with defecation frequency 3 or less/ 9 or more per weeks.
11. Subjects with stool characteristics (Bristol scale) 5 or more.
12. Subjects who have habit to consume yogurt 6 days or more per week.
13. Subjects who have habit to consume beverages include lactic acid bacteria and/or bifidobacteria 2 days or more per week.
14. Subjects who have habit to consume beverages include dietary fiber reinforced food and/or oligo sugar 1 day or more per week.
15. Subjects who have allergy to drugs or foods especially based on soybean and yeast.
16. Subjects who used antibiotics within 12 weeks, prior to the current study.
17. Heavy smokers, alcohol addicts or subjects with disordered lifestyle.
18. Subjects who donated either 400 ml whole blood within 16 weeks (women), 12 weeks (men), 200 ml whole blood within 4 weeks, or blood components within 2 week, prior to the study.
19. Pregnant or lactating women or women who expect to be pregnant during this study.
20. Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the study.
21. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Naoyuki
Middle name
Last name HONMA

Organization

Hokkaido Information University

Division name

Department of Medical Management and Informatics

Zip code

069-8585

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4411

Email

hisc-acad.res@s.do-johodai.ac.jp


Public contact

Name of contact person

1st name Naoyuki
Middle name
Last name HONMA

Organization

Hokkaido Information University

Division name

Health Information Science Center

Zip code

069-8585

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

TEL

011-385-4430

Homepage URL


Email

hisc-acad.res@s.do-johodai.ac.jp


Sponsor or person

Institute

Hokkaido Information University

Institute

Department

Personal name



Funding Source

Organization

National Agriculture and Food Research Organization

Organization

Division

Category of Funding Organization

Government offices of other countries

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

National Agriculture and Food Research Organization
National Institute of Advanced Industrial Science and Technology
Bioresource and Bioenvironment Kyushu University

Name of secondary funder(s)

Asahi Quality & Innovations, Ltd.


IRB Contact (For public release)

Organization

The ethics committee of Hokkaido Information University

Address

59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan

Tel

011-385-4411

Email

soumu@do-johodai.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道情報大学 保健センター(北海道)


Other administrative information

Date of disclosure of the study information

2022 Year 08 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 04 Month 28 Day

Date of IRB

2021 Year 04 Month 28 Day

Anticipated trial start date

2021 Year 06 Month 30 Day

Last follow-up date

2021 Year 09 Month 09 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 05 Month 11 Day

Last modified on

2022 Year 04 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050427


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name